EPISODE · Nov 11, 2024 · 18 MIN
Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147
from ACCP JOURNALS · host ACCP JOURNALS
Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.
What this episode covers
Explore the basis for and controversy surrounding the US Food and Drug Administration requiring a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2034.
NOW PLAYING
Should the FDA be requiring a Risk Evaluation and Mitigation Strategy for mifepristone? - Ep 147
No transcript for this episode yet
Similar Episodes
Jun 22, 2026 ·12m
Jun 22, 2026 ·25m
Jun 22, 2026 ·24m
Jun 21, 2026 ·30m
Jun 20, 2026 ·37m